PURPOSE: Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion protein consisting of a mutated variant of the superantigen staphylococcal enterotoxin E (SEA/E-120) linked to fragment antigen binding moiety of a monoclonal antibody recognizing the tumor-associated antigen 5T4. PATIENTS AND METHODS: Patients with non-small-cell lung cancer (NSCLC), pancreatic cancer (PC), and renal cell cancer (RCC) received 5 daily boluses of ABR-217620 (3-month cycles) in escalating doses to determine the maximum-tolerated dose (MTD; ABR-217620 dose escalation monotherapy [MONO] study). Doses were selected based on individual patient anti-SEA/E-120 titers pretreatment. Patients with NSCLC received 4 daily, escalating doses of ABR-217620 followed by docetaxel in 21-day cycles (ABR-217620 dose escalation combination with docetaxel [COMBO] study). RESULTS: Thirty-nine patients were enrolled in the MONO study and 13 were enrolled in the COMBO study. The monotherapy MTD was 26 microg/kg (NSCLC and PC) and 15 microg/kg (RCC). Dose-limiting toxicities (DLTs) in the MONO study were fever, hypotension, acute liver toxicity, and vascular leak syndrome. In the COMBO study, the MTD was 22 microg/kg (neutropenic sepsis). Adverse events included grade 1 to 2 fever, hypotension, nausea, and chills. Treatment caused a systemic increase of inflammatory cytokines and selective expansion of SEA/E-120 reactive T-cells. Tumor biopsies demonstrated T-cell infiltration after therapy. Fourteen patients (36%) had stable disease (SD) on day 56 of the MONO study. Two patients (15%) in the COMBO study had partial responses, one in a patient with progressive disease on prior docetaxel, and five patients (38%) had SD on day 56. CONCLUSION: ABR-217620 was well tolerated with evidence of immunological activity and antitumor activity.
PURPOSE: Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion protein consisting of a mutated variant of the superantigen staphylococcal enterotoxin E (SEA/E-120) linked to fragment antigen binding moiety of a monoclonal antibody recognizing the tumor-associated antigen 5T4. PATIENTS AND METHODS: Patients with non-small-cell lung cancer (NSCLC), pancreatic cancer (PC), and renal cell cancer (RCC) received 5 daily boluses of ABR-217620 (3-month cycles) in escalating doses to determine the maximum-tolerated dose (MTD; ABR-217620 dose escalation monotherapy [MONO] study). Doses were selected based on individual patient anti-SEA/E-120 titers pretreatment. Patients with NSCLC received 4 daily, escalating doses of ABR-217620 followed by docetaxel in 21-day cycles (ABR-217620 dose escalation combination with docetaxel [COMBO] study). RESULTS: Thirty-nine patients were enrolled in the MONO study and 13 were enrolled in the COMBO study. The monotherapy MTD was 26 microg/kg (NSCLC and PC) and 15 microg/kg (RCC). Dose-limiting toxicities (DLTs) in the MONO study were fever, hypotension, acute liver toxicity, and vascular leak syndrome. In the COMBO study, the MTD was 22 microg/kg (neutropenic sepsis). Adverse events included grade 1 to 2 fever, hypotension, nausea, and chills. Treatment caused a systemic increase of inflammatory cytokines and selective expansion of SEA/E-120 reactive T-cells. Tumor biopsies demonstrated T-cell infiltration after therapy. Fourteen patients (36%) had stable disease (SD) on day 56 of the MONO study. Two patients (15%) in the COMBO study had partial responses, one in a patient with progressive disease on prior docetaxel, and five patients (38%) had SD on day 56. CONCLUSION: ABR-217620 was well tolerated with evidence of immunological activity and antitumor activity.
Authors: E L Sievers; F R Appelbaum; R T Spielberger; S J Forman; D Flowers; F O Smith; K Shannon-Dorcy; M S Berger; I D Bernstein Journal: Blood Date: 1999-06-01 Impact factor: 22.113
Authors: B J Giantonio; R K Alpaugh; J Schultz; C McAleer; D W Newton; B Shannon; Y Guedez; M Kotb; L Vitek; R Persson; P O Gunnarsson; T Kalland; M Dohlsten; B Persson; L M Weiner Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: Robert J Kreitman; David R Squires; Maryalice Stetler-Stevenson; Pierre Noel; David J P FitzGerald; Wyndham H Wilson; Ira Pastan Journal: J Clin Oncol Date: 2005-08-01 Impact factor: 44.544
Authors: M Dohlsten; L Abrahmsén; P Björk; P A Lando; G Hedlund; G Forsberg; T Brodin; N R Gascoigne; C Förberg; P Lind Journal: Proc Natl Acad Sci U S A Date: 1994-09-13 Impact factor: 11.205
Authors: D M Shaw; N B Connolly; P M Patel; S Kilany; G Hedlund; O Nordle; G Forsberg; J Zweit; P L Stern; R E Hawkins Journal: Br J Cancer Date: 2007-02-06 Impact factor: 7.640
Authors: Filip Janku; Apostolia M Tsimberidou; Xuemei Wang; David S Hong; Aung Naing; Jing Gong; Ignacio Garrido-Laguna; Henrique A Parsons; Ralph G Zinner; Razelle Kurzrock Journal: Oncologist Date: 2011-02-21
Authors: F V Castro; O J McGinn; S Krishnan; G Marinov; J Li; A J Rutkowski; E Elkord; D J Burt; M Holland; R Vaghjiani; A Gallego; V Saha; P L Stern Journal: Leukemia Date: 2012-01-23 Impact factor: 11.528